SMARCA4-DEFICIENT TUMOR
Clinical trials for SMARCA4-DEFICIENT TUMOR explained in plain language.
Never miss a new study
Get alerted when new SMARCA4-DEFICIENT TUMOR trials appear
Sign up with your email to follow new studies for SMARCA4-DEFICIENT TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets 'Undruggable' lung cancer
Disease control Not yet recruitingThis study is testing a new combination treatment for people with a specific, hard-to-treat form of advanced lung cancer (SMARCA4-deficient). All participants will receive an oral pill called anlotinib alongside standard platinum-based chemotherapy. The main goals are to see if t…
Matched conditions: SMARCA4-DEFICIENT TUMOR
Phase: PHASE2 • Sponsor: Zhijie Wang • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
New hope for deadly lung cancer? trial tests promising drug combo
Disease control Not yet recruitingThis study is testing a new combination treatment for people with an aggressive, hard-to-treat type of advanced lung cancer. It combines a new two-in-one immunotherapy drug (which targets two different immune system pathways) with standard chemotherapy. The goal is to see if this…
Matched conditions: SMARCA4-DEFICIENT TUMOR
Phase: PHASE2 • Sponsor: Zhijie Wang • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC